Related Experiment Video
Updated: Aug 13, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
Published on: November 2, 2014
Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven
P Giannakakou1, D L Sackett, Y K Kang
1Medicine Branch, Division of Clinical Sciences, NCI, National Institutes of Health, Bethesda, Maryland 20892, USA.
Abstract:
Acquired resistance to paclitaxel can be mediated by P-glycoprotein or by alterations involving tubulin. We report two paclitaxel-resistant sublines derived from 1A9 human ovarian carcinoma cells. Single-step paclitaxel selection with verapamil yielded two clones that are resistant to paclitaxel and collaterally sensitive to vinblastine. The resistant sublines are not paclitaxel-dependent, and resistance remained stable after 3 years of drug-free culture. All cell lines accumulate [3H]paclitaxel equally, and no MDR-1 mRNA was detected by polymerase chain reaction following reverse transcription. Total tubulin content is similar, but the polymerized fraction increased in parental but not in resistant cells following the paclitaxel addition. Purified tubulin from parental cells demonstrated paclitaxel-driven increased polymerization, in contrast to resistant cell tubulin, which did not polymerize under identical conditions. In contrast, epothilone B, an agent to which the resistant cells retained sensitivity, increased assembly. Comparable expression of beta-tubulin isotypes was found in parental and resistant cells, with predominant expression of the M40 and beta2 isotypes. Sequence analysis demonstrated acquired mutations in the M40 isotype at nucleotide 810 (T --> G; Phe270 --> Val) in 1A9PTX10 cells and nucleotide 1092 (G --> A; Ala364 --> Thr) in 1A9PTX22 cells. These results identify residues beta270 and beta364 as important modulators of paclitaxel's interaction with tubulin.
Insights
Paclitaxel resistance in ovarian cancer cells can stem from tubulin alterations, not P-glycoprotein. Mutations in beta-tubulin residues Phe270 and Ala364 confer paclitaxel resistance by affecting drug interaction with tubulin.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Acquired resistance to paclitaxel, a key chemotherapy drug, is a significant clinical challenge in ovarian cancer treatment.
- Resistance mechanisms often involve P-glycoprotein efflux or alterations in the target molecule, tubulin.
Purpose of the Study:
- To investigate novel mechanisms of paclitaxel resistance in human ovarian carcinoma cells.
- To identify specific molecular changes in tubulin that contribute to paclitaxel resistance.
Main Methods:
- Development of paclitaxel-resistant sublines (1A9PTX10, 1A9PTX22) from 1A9 human ovarian carcinoma cells.
- Analysis of drug accumulation, P-glycoprotein expression (MDR-1 mRNA), and tubulin polymerization dynamics.
- Sequencing of beta-tubulin isotypes to identify mutations.
Main Results:
- Resistant cells showed no P-glycoprotein involvement and equal drug accumulation but impaired paclitaxel-induced tubulin polymerization.
- Mutations were identified in the M40 beta-tubulin isotype at Phe270Val (1A9PTX10) and Ala364Thr (1A9PTX22).
- These mutations altered tubulin's response to paclitaxel but not epothilone B, to which cells remained sensitive.
Conclusions:
- Paclitaxel resistance in these ovarian cancer sublines is mediated by specific mutations in beta-tubulin.
- Residues Phe270 and Ala364 are critical for paclitaxel's interaction with tubulin, influencing polymerization and conferring resistance.
- These findings offer insights into drug resistance mechanisms and potential therapeutic strategies.
Related Concept Videos
Destabilization of Microtubules
Drugs that Stabilize Microtubules
Abnormal Proliferation
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Drugs that Destabilize Microtubules

